Participant flow

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer · Source last updated 2019-12-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Arm 1 (patients with lower risk of graft failure-have received multi-agent chemotherapy in the prior 2 months or history of prior autologous transplant): Patients undergo 200 cGy TBI on day -1. Arm 2 (patients at higher risk of graft failure-have not received multi agent chemotherapy in the prior 2 months and no history of prior autologous transplant): Patients undergo 300 cGy TBI on day -1 UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0. IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96.

   id

   FG000

   title

   Arm 1 and 2 Treatment

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         73

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         72

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice